Monte Rosa Therapeutics, Inc. (GLUE) total debt
Monte Rosa Therapeutics, Inc. (GLUE) carried total debt of $39.19M at the end of fiscal 2025 (December 31, 2025). That is 8.3% lower than the $42.72M of fiscal 2024. Figures as of 18 Nov 2026, 04:25 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $39.19M
- Change on fiscal 2024
- −8.3%
- Highest on record
- $47.00Mfiscal 2022
- Lowest on record
- $39.19Mfiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Monte Rosa Therapeutics, Inc. total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $47.00M in fiscal 2022 and the lowest $39.19M in fiscal 2025.
Total debt was 0.2× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Monte Rosa Therapeutics, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $39.19M | 8.3% down | 0.2× | |
| 2024 | $42.72M | 7.2% down | 0.2× | |
| 2023 | $46.04M | 2.0% down | 0.3× | |
| 2022 | $47.00M | — | 0.2× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Monte Rosa Therapeutics, Inc., figure by figure
- Monte Rosa Therapeutics, Inc. market cap
- Monte Rosa Therapeutics, Inc. revenue
- Monte Rosa Therapeutics, Inc. earnings
- Monte Rosa Therapeutics, Inc. earnings per share (EPS)
- Monte Rosa Therapeutics, Inc. P/E ratio
- Monte Rosa Therapeutics, Inc. P/S ratio
- Monte Rosa Therapeutics, Inc. P/B ratio
- Monte Rosa Therapeutics, Inc. free cash flow
- Monte Rosa Therapeutics, Inc. operating margin
- Monte Rosa Therapeutics, Inc. dividend
- Monte Rosa Therapeutics, Inc. shares outstanding
- Monte Rosa Therapeutics, Inc. cash on hand
- Monte Rosa Therapeutics, Inc. total assets
- Monte Rosa Therapeutics, Inc. return on equity (ROE)
- Monte Rosa Therapeutics, Inc. return on invested capital (ROIC)
Monte Rosa Therapeutics, Inc. (GLUE) overview: price, valuation and scorecard
Monte Rosa Therapeutics, Inc. total debt: questions and answers
How much debt does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. (GLUE) carried total debt of $39.19M at the end of fiscal 2025 (December 31, 2025). That is 8.3% lower than the $42.72M of fiscal 2024.
What are the highest and lowest total debt figures on record for Monte Rosa Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $47.00M in fiscal 2022 and the lowest $39.19M in fiscal 2025.
How does Monte Rosa Therapeutics, Inc.'s debt compare with its equity?
Total debt was 0.2× shareholders' equity at the end of fiscal 2025.
How is Monte Rosa Therapeutics, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Monte Rosa Therapeutics, Inc. (GLUE) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/GLUE/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.